The goal of this clinical trial is to test the therapeutic effect of Semaglutide in NAFLD and
its sequelae in obesity and/or type 2 diabetes mellitus. The main question it aims to answer
is:
• Is the use of Semaglutide (oral or subcutaneous form) effective in improving NAFLD and its
sequelae in obesity and/or type 2 diabetes mellitus?
Participants will undergo:
- Abdominal ultrasound.
- Fibroscan with controlled attenuation parameter to assess liver stiffness (kPa) and
liver steatosis (dB/m).
- Fibrosis-4 score requires values of age, alanine aminotransferase, aspartate
aminotransferase, and platelet count.
- NAFLD Fibrosis Score requires values of age, BMI, platelet count, albumin,
hyperglycemia, and ALT/AST ratio.
Researchers will compare:
- Group 1 will receive oral Semaglutide for 48 weeks.
- Group 2 will receive injectable Semaglutide for 48 weeks.
- Group 3 will receive Pioglitazone and/or Vitamin E. to see if there is an improvement in
liver stiffness and severity of hepatic steatosis after 48 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Zagazig University
Treatments:
alpha-Tocopherol Tocopherols Tocotrienols Vitamin E